A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists
← catalyst calendarSponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
10actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-10 | actual | When the study began enrolling |
| Primary completion | 2025-04-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-24 | actual | The whole study's end, after follow-up |
| First posted | 2025-02-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pain
Intervention
- Drug: SUZ — also filed as VX-548
Primary outcome
what the primary-completion date above is the date OFFlavor Assessment Based on Flavor Profile Method of Descriptive Sensory Analysis per American Society for Testing and Material (ASTM) Approved Sensory Evaluation Method
measured Periodic Intervals up to 30 minutes post oral administration
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed